Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
Flawless balance sheet with high growth potential.
Share Price & News
How has Illumina's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ILMN's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: ILMN underperformed the US Life Sciences industry which returned 22.9% over the past year.
Return vs Market: ILMN exceeded the US Market which returned 8.4% over the past year.
Price Volatility Vs. Market
How volatile is Illumina's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIllumina (NASDAQ:ILMN) Has A Rock Solid Balance Sheet
2 months ago | Simply Wall StHow Does Illumina's (NASDAQ:ILMN) P/E Compare To Its Industry, After The Share Price Drop?
2 months ago | Simply Wall StDoes Illumina, Inc.'s (NASDAQ:ILMN) CEO Salary Reflect Performance?
Is Illumina undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ILMN ($363.05) is trading above our estimate of fair value ($183.08)
Significantly Below Fair Value: ILMN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ILMN is poor value based on its PE Ratio (56.7x) compared to the Life Sciences industry average (36x).
PE vs Market: ILMN is poor value based on its PE Ratio (56.7x) compared to the US market (16x).
Price to Earnings Growth Ratio
PEG Ratio: ILMN is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: ILMN is overvalued based on its PB Ratio (11.5x) compared to the US Life Sciences industry average (5.7x).
How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ILMN's forecast earnings growth (24% per year) is above the savings rate (2.2%).
Earnings vs Market: ILMN's earnings (24% per year) are forecast to grow faster than the US market (21.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ILMN's revenue (12.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: ILMN's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ILMN's Return on Equity is forecast to be high in 3 years time (21.3%)
How has Illumina performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ILMN has high quality earnings.
Growing Profit Margin: ILMN's current net profit margins (26.5%) are higher than last year (25%).
Past Earnings Growth Analysis
Earnings Trend: ILMN's earnings have grown by 17.6% per year over the past 5 years.
Accelerating Growth: ILMN's earnings growth over the past year (10.7%) is below its 5-year average (17.6% per year).
Earnings vs Industry: ILMN earnings growth over the past year (10.7%) exceeded the Life Sciences industry 10.6%.
Return on Equity
High ROE: ILMN's Return on Equity (20.3%) is considered high.
How is Illumina's financial position?
Financial Position Analysis
Short Term Liabilities: ILMN's short term assets ($4.3B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: ILMN's short term assets ($4.3B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: ILMN's debt to equity ratio (24.8%) is considered satisfactory.
Reducing Debt: ILMN's debt to equity ratio has reduced from 80% to 24.8% over the past 5 years.
Debt Coverage: ILMN's debt is well covered by operating cash flow (98.5%).
Interest Coverage: ILMN earns more interest than it pays, so coverage of interest payments is not a concern.
What is Illumina's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ILMN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ILMN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ILMN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ILMN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ILMN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Francis deSouza (48yo)
Mr. Francis A. deSouza has been the Chief Executive Officer of Illumina Inc. since July 5, 2016 and as its President since December, 2013. Mr. deSouza served as President of Products & Services at Symantec ...
CEO Compensation Analysis
Compensation vs Market: Francis's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD11.71M).
Compensation vs Earnings: Francis's compensation has been consistent with company performance over the past year.
|CEO, President & Director||3.83yrs||US$1.52m||0.043% $23.0m|
|CFO & Senior VP||3.33yrs||US$626.70k||0.00092% $491.0k|
|Senior VP and Chief Product & Marketing Officer||3.33yrs||US$744.10k||0.0069% $3.7m|
|Senior VP of Corporate Development & Strategic Planning||0.67yr||US$1.98m||no data|
|Chief People Officer & Senior VP||2.33yrs||US$864.07k||0.00013% $69.4k|
|Senior Vice President of Global Quality & Operations||7.33yrs||no data||0.0088% $4.7m|
|VP & Chief Accounting Officer||2.5yrs||no data||0.0013% $672.4k|
|Vice President of IR||0.17yr||no data||no data|
|Senior VP||7.08yrs||US$1.73m||0.0038% $2.0m|
|Senior Director of Corporate Communications||no data||no data||no data|
Experienced Management: ILMN's management team is considered experienced (3.3 years average tenure).
|CEO, President & Director||3.83yrs||US$1.52m||0.043% $23.0m|
|Lead Independent Director||2yrs||US$500.20k||0.0034% $1.8m|
|Independent Director||3.33yrs||US$501.48k||0.0050% $2.7m|
|Independent Director||1.17yrs||US$1.26m||0.0014% $731.1k|
|Independent Director||3.83yrs||US$476.85k||0.0053% $2.8m|
|Independent Director||7.5yrs||US$497.62k||0.0034% $1.8m|
|Independent Director||2.42yrs||US$491.85k||0.0027% $1.4m|
|Independent Director||4.33yrs||US$481.85k||0.0059% $3.1m|
|Independent Director||0.17yr||no data||no data|
Experienced Board: ILMN's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Illumina, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Illumina, Inc.
- Ticker: ILMN
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$53.368b
- Shares outstanding: 147.00m
- Website: https://www.illumina.com
Number of Employees
- Illumina, Inc.
- 5200 Illumina Way
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ILMN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2000|
|ILU||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2000|
|ILU||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jul 2000|
|ILMN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 2000|
|ILMN||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jul 2000|
|0J8Z||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 2000|
|ILU||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jul 2000|
|I1LM34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 5 REPR 1 COM||BR||BRL||Jan 2020|
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/30 02:45|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.